Catalog4 refs
CagriSema
MetabolicResearch use only
Educational use only. Not medical advice. Verify all information with primary sources and a licensed clinician before use.
Body Map
Overview
A once-weekly injectable combination of semaglutide (a GLP-1 receptor agonist) and cagrilintide (a long-acting amylin analog) being developed by Novo Nordisk for obesity and type 2 diabetes. It works on two different appetite systems at once to produce more appetite suppression than either component alone.
Primary Uses
Weight management
Obesity
Type 2 diabetes
Protocol Reference
Dose
Semaglutide 2.4mg + Cagrilintide 2.4mg weekly
Frequency
Weekly
Route
Subcutaneous injection
Evidence
Phase 3 Clinical Trials
Research References· 1
Research Models
Human
Also in Metabolic